Marshall Wace’s MoonLake Immunotherapeutics MLTX Stock Holding History

Marshall Wace’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.08M	Buy	+111,331	New	+$1.84M	﹤0.01%	1763
2025 Q4	–	Sell	-321,109	Closed	-$2.3M	–	3268
2025 Q3	$2.3M	Sell	321,109 -208,102	-39%	-$10.8M	﹤0.01%	1547
2025 Q2	$25M	Sell	529,211 -111,706	-17%	-$4.55M	0.03%	505
2025 Q1	$25M	Sell	640,917 -604,382	-49%	-$26M	0.03%	458
2024 Q4	$67.4M	Buy	1,245,299 +90,914	+8%	+$4.64M	0.08%	222
2024 Q3	$58.2M	Buy	1,154,385 +55,755	+5%	+$2.61M	0.07%	241
2024 Q2	$48.3M	Buy	1,098,630 +587,684	+115%	+$24.9M	0.06%	272
2024 Q1	$25.7M	Buy	+510,946	New	+$27.7M	0.04%	430
2023 Q4	–	Sell	-30,451	Closed	-$1.74M	–	2449
2023 Q3	$1.74M	Sell	30,451 -27,932	-48%	-$1.54M	﹤0.01%	1288
2023 Q2	$2.98M	Buy	+58,383	New	+$1.57M	0.01%	1226
2022 Q2	–	Sell	-653,872	Closed	-$7.26M	–	3690
2022 Q1	$7.26M	Buy	653,872 +120,968	+23%	+$1.2M	0.01%	1105
2021 Q4	$5.27M	Buy	+532,904	New	+$5.3M	0.01%	1313

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace's MLTX Position: Q1 2026 in Review

Marshall Wace opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 111,331 shares worth $2.08M. The stake represents ﹤0.01% of the portfolio and ranks #1763 among its holdings. This is a return to the name: Marshall Wace previously reported a position in MLTX as recently as Q3 2025.

Marshall Wace first reported a position in MLTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $67.4M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Marshall Wace held 111,331 shares of MoonLake Immunotherapeutics worth $2.08M as of Q1 2026.
MoonLake Immunotherapeutics was a new Marshall Wace position in Q1 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1763 holding.
Marshall Wace first reported a position in MoonLake Immunotherapeutics in Q4 2021 and has held it in 12 quarters since.
Marshall Wace's MoonLake Immunotherapeutics position peaked at $67.4M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.